Inhibition of the innate immune system to disrupt “Don’t Eat Me” signals between tumor and macrophages is a rapidly growing area of drug development. LILRB1 and LILRB2 are two such immunomodulatory receptors but targeting them poses the challenges of avoiding ten highly homologous LILR family members that are also expressed on myeloid cells.  This presentation provides a rational and successful approach for overcoming these challenges utilizing a fully human, highly diverse antibody phage display library. It will also cover the next stages of antibody discovery and development, reviewing the in vitro and in vivo characterization required to go from antibody discovery to clinical candidate.